Hepion Pharmaceuticals, Inc.
HEPA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.01 | -0.03 |
| FCF Yield | -151.76% | -91.63% | -35.24% | -56.09% |
| EV / EBITDA | 1.23 | 0.47 | 1.78 | -1.17 |
| Quality | ||||
| ROIC | -40.74% | -21.67% | -87.76% | -138.33% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 1.32 | 0.18 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -23.08% | 3.08% | 54.21% | 76.96% |
| Safety | ||||
| Net Debt / EBITDA | 1.90 | 0.67 | 0.77 | -0.16 |
| Interest Coverage | -358.72 | -51.61 | -1.47 | -9.39 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |